AveXis, Inc. Report issue

Contributed to NME For profit Phase 4
Founded: Dallas TX United States (2013)
Status: Acquired by Novartis (2018)

Organization Overview

First Clinical Trial
2014
NCT02122952
First Marketed Drug
2013
onasemnogene abeparvovec (Zolgensma)
First NDA Approval
2019
onasemnogene abeparvovec (Zolgensma)
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

AveXis, Inc.

Active Ingredients

Marketed Drugs (1)

onasemnogene abeparvovec (Zolgensma) (2019 NDA)

Drugs in Phase 4 Trials (1)

onasemnogene abeparvovec (Zolgensma) (8 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 4)

Muscular Atrophy (Phase 4)

Muscular Atrophy, Spinal (Phase 4)

Spinal Muscular Atrophies of Childhood (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 1